Pseudotyped Lentiviral Vectors: One Vector, Many Guises

Joglekar, Archis; Sandoval, Salemiz

doi:10.1089/hgtb.2017.084

Cited by 75 publications

(60 citation statements)

References 97 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poor lung transduction rates observed with the canonical VSV-G pseudotype led to the development of novel lentiviral pseudotypes with improved transduction efficiencies (reviewed in [35]). A lentiviral pseudotype based on the envelope proteins of the lung-tropic Sendai virus (Figure 3(b)) has shown promising results in pre-clinical models and is poised for clinical trial [36,37].…”

Section: A Brief History Of In-vivo Gene Therapymentioning

confidence: 99%

“…The baculovirus-derived GP64 protein appears to display greater liver tropism compared with VSV-G, which leads to more significant transduction and higher transgene expression profile in mice [65,66]. Other pseudotypes, such as those derived from alphaviruses Ross River virus or Semliki Forest virus, are able to efficiently transduce both hepatocytes and Kupffer cells [35]. Transduction of these cells, which can exhibit antigen display properties, could be detrimental through the induction of a cellular immune response against both viral structural proteins and the therapeutic transgene protein, and should be avoided.…”

Section: A Brief History Of In-vivo Gene Therapymentioning

confidence: 99%

See 1 more Smart Citation

Lessons learned from lung and liver in-vivo gene therapy: implications for the future

Haasteren

Hyde

Gill

2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: Ex-vivo gene therapy has had significant clinical impact over the last couple of years and in-vivo gene therapy products are being approved for clinical use. Gene therapy and gene editing approaches have huge potential to treat genetic disease and chronic illness. Areas covered: This article provides a review of in-vivo approaches for gene therapy in the lung and liver, exploiting non-viral and viral vectors with varying serotypes and pseudotypes to target-specific cells. Antibody responses inhibiting viral vectors continue to constrain effective repeat administration. Lessons learned from ex-vivo gene therapy and genome editing are also discussed. Expert opinion: The fields of lung and liver in-vivo gene therapy are thriving and a comparison highlights obstacles and opportunities for both. Overcoming immunological issues associated with repeated administration of viral vectors remains a key challenge. The addition of targeted small molecules in combination with viral vectors may offer one solution. A substantial bottleneck to the widespread adoption of in-vivo gene therapy is how to ensure sufficient capacity for clinical-grade vector production. In the future, the exploitation of gene editing approaches for in-vivo disease treatment may facilitate the resurgence of non-viral gene transfer approaches, which tend to be eclipsed by more efficient viral vectors.

show abstract

Section: A Brief History Of In-vivo Gene Therapymentioning

confidence: 99%

Section: A Brief History Of In-vivo Gene Therapymentioning

confidence: 99%

Lessons learned from lung and liver in-vivo gene therapy: implications for the future

Haasteren

Hyde

Gill

2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…The best correlate of protection is viral neutralization. To this end, we generated pseudotyped retroviruses 12 expressing the SARS-CoV-2 spike protein and luciferase for quantification of infection ( Fig. 4a).…”

Section: Mainmentioning

confidence: 99%

Development of a vaccine against the newly emerging COVID-19 virus based on the receptor binding domain displayed on virus-like particles

Zhao

et al. 2020

Preprint

View full text Add to dashboard Cite

The recently ermerging disease COVID-19 is caused by the new SARS-CoV-2 virus first detected in the city of Wuhan, China. From there it has been rapidly spreading inside and outside China. With initial death rates around 4%, COVID-19 patients at longer distances from Wuhan showed reduced mortality as was previously observed for the SARS coronavirus. However, the new coronavirus spreads more strongly, as it sheds long before onset of symptoms or may be transmitted by people without symptoms. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here we demonstrate that recombinantly expressed receptor binding domain (RBD) of the spike protein homologous to SARS binds to ACE2, the viral receptor. Higly repetitive display of RBD on immunologically optimized virus-like particles derived from cucumber mosaic virus resulted in a vaccine candidate (RBD-CuMVTT) that induced high levels of specific antibodies in mice which were able to block binding of spike protein to ACE2 and potently neutralized the SARS-CoV-2 virus in vitro.

show abstract

“…human diseases [42]. The last generation of HIV LVs are highly improved in their efficiency of transgene delivery and in their safety level.…”

Section: Retroviral Vectors (Rvs)mentioning

confidence: 99%

“…While the most common example is the VSV-G pseudotyped RV, many other viral glycoproteins have also been successfully used, such EBOV and Lassa virus as the one of highly pathogenic viruses. EBOV pseudotyped RVs lead to targeted transduction of specific cell types, allowing the study of the viral entry mechanism and the screening of compound libraries with the aim of identifying compounds able to block viral entry [42].…”

Section: Retroviral Vectors (Rvs)mentioning

confidence: 99%

Ebolavirus Entry: From Molecular Characterization to Drug Discovery

Salata¹,

Calistri²,

Alvisi³

et al. 2019

Preprint

View full text Add to dashboard Cite

Ebola Virus Disease (EVD) is one of the most lethal transmissible infections characterized by a high fatality rate, and caused by members of the Filoviridae family. The recent large outbreak of EVD in West Africa (2013-2016), highlighted the worldwide danger of this disease and its impact on global public health and economy. The development of highly needed anti-Filoviridae antivirals has been so far hampered by the shortage of tools to study their life cycle in vitro, and therefore screen for potential active compounds outside a biosafety level-4 (BSL-4) containment. Importantly, the development of surrogate models to in vitro study of Filoviridae entry in a BSL-2 setting, such as viral pseudotypes and Ebola virus like particles, tremendously boosted both our knowledge on viral life cycle and the identification of promising anti-Filoviridae compounds interfering with viral entry. In this context, the combination of such surrogate systems with large-scale small molecule compounds and haploid genetic screenings, as well as rational drug design and drug repurposing approaches will prove priceless in our quest for the development of a treatment for EVD.

show abstract

Pseudotyped Lentiviral Vectors: One Vector, Many Guises

Cited by 75 publications

References 97 publications

Lessons learned from lung and liver in-vivo gene therapy: implications for the future

Lessons learned from lung and liver in-vivo gene therapy: implications for the future

Development of a vaccine against the newly emerging COVID-19 virus based on the receptor binding domain displayed on virus-like particles

Ebolavirus Entry: From Molecular Characterization to Drug Discovery

Contact Info

Product

Resources

About